MyFinsight
Home
Blog
About
Contact
Download
Download image
Net income from
operations
$9,880K
Stock-based compensation
$7,157K
Depreciation and
amortization
$2,481K
Accrued expenses and
other liabilities
$946K
Noncash lease expense
$777K
Equity loss of
unconsolidated affiliates
-$77K
Income tax payable
$44K
Change in fair value of
derivative liabilities
$39K
Amortization of land use
rights
$39K
Accrued interest on bank
deposit
-$28K
Net proceeds from
cvr liability...
$25K
Accounts payable
$13K
Net cash provided by
financing activities
$24,378K
Net Cash Provided By
Used In Operating...
$1,000K
Effect of exchange rate
changes on cash and cash...
$343K
Canceled cashflow
$20,500K
Net increase
(decrease) in cash and cash...
$25,257K
Canceled cashflow
$474K
Accounts receivable
$10,806K
Inventories
$3,631K
Change in fair value of
warrant liability
-$2,707K
Notes receivable
$1,147K
Deferred income taxes,
net
-$1,109K
Operating lease
liabilities
-$744K
Prepaid and other assets
$206K
Bad debt expense and
other non-cash items
-$63K
Other noncurrent
liabilities
-$47K
Change in fair value of
receivables from gcbp
$39K
Due to related
parties
-$1K
Maturity of certificates
of deposit
$15,429K
Proceeds from sale of
equipment
$30K
Net cash used in
investing activities
-$474K
Canceled cashflow
$15,459K
Purchase of certificates
of deposit
$14,010K
Purchases of property and
equipment
$1,190K
Acquisition of intangible
assets
$733K
Back
Back
Cash Flow
source: myfinsight.com
GYRE THERAPEUTICS, INC. (GYRE)
GYRE THERAPEUTICS, INC. (GYRE)